Pharmacology, Toxicology and Pharmaceutical Science
Urinary Tract Infection
100%
Antiinfective Agent
67%
Clinical Study
56%
Escherichia coli
53%
Infection
46%
Prostatitis
38%
Quinolone Derivative
30%
Pyelonephritis
29%
Levofloxacin
27%
Infectious Agent
21%
Klebsiella pneumoniae
20%
Cystitis
20%
Enterococcus faecalis
20%
Pseudomonas aeruginosa
18%
Neisseria gonorrhoeae
18%
Cefoselis
18%
Staphylococcus Saprophyticus
18%
Urethritis
18%
Urogenital Tract Infection
18%
Extended Spectrum Beta Lactamase
16%
Biapenem
15%
Antibiotics
15%
Minimum Inhibitory Concentration
14%
Penicillinase
13%
Bladder Cancer
10%
Genital Tract Infection
10%
Side Effect
9%
Cranberry
9%
Retrospective Study
9%
Piperacillin Plus Tazobactam
9%
Carbapenem Derivative
9%
Pazufloxacin
9%
Neutrophil Gelatinase Associated Lipocalin
9%
Holmium
9%
Neoplasm
9%
Fleroxacin
9%
Ritipenem Acoxil
9%
Chlamydia Trachomatis
9%
Rat Model
9%
Disease
9%
Vancomycin-Resistant Enterococcus
9%
Fropenem
9%
Temafloxacin
9%
Cefozopran
9%
Cefluprenam
9%
Clinical Feature
9%
Alanine Aminotransferase
8%
Cephem Derivative
7%
Symptom
7%
Postoperative Infection
7%
Keyphrases
Levofloxacin
28%
Nationwide Surveillance
27%
Piperacillin
20%
Escherichia Coli
19%
Neisseria Gonorrhoeae
18%
Male Urethritis
18%
Recurrent Urinary Tract Infections (rUTIs)
18%
Antimicrobial Susceptibility Pattern
18%
Surveillance Program
18%
Bacterial Isolates
18%
Bacterial Strains
17%
Fluoroquinolones
16%
Japan
16%
Bacterial Pathogens
16%
Minimum Inhibitory Concentration
15%
Japanese Society
15%
Extended-spectrum-lactamase
14%
Staphylococcus Saprophyticus
13%
Klebsiella Pneumoniae (K. pneumoniae)
12%
Antimicrobial Susceptibility
11%
Antimicrobial
11%
Tazobactam
11%
Acute Cystitis
10%
Resistant Strains
10%
Enterococcus Faecalis
9%
Biological Profile
9%
Urinary Tract Infection
9%
Escherichia Coli Isolates
9%
Renal Abscess
9%
Cranberry Juice
9%
Japanese Studies
9%
Prophylactic Antibiotics
9%
Penem
9%
Fleroxacin
9%
Quinolone Derivatives
9%
Male Genital
9%
Imipenem-cilastatin
9%
Comparative Susceptibility
9%
Radical Cystectomy
9%
Fimbrial
9%
Bladder Infection
9%
Cognate Receptors
9%
Pyonephrosis
9%
Upper Urinary Tract Infection
9%
Robot-assisted Laparoscopic Partial Nephrectomy
9%
RNA Kinetics
9%
Transurethral Enucleation
9%
Localized Kidney Cancer
9%
Transurethral Enucleation of the Prostate
9%
Surgical Systems
9%
Medicine and Dentistry
Antiinfective Agent
29%
Urinary Tract Infection
21%
Infection
20%
Prostatitis
18%
Antibiotics
12%
Cystectomy
10%
Levofloxacin
10%
Prostate Biopsy
10%
Urinary Diversion
10%
Urologist
9%
Escherichia coli
9%
Legionella
9%
Holmium
9%
Brain Death
9%
Enucleation
9%
Kidney Abscess
9%
Retrospective Study
9%
Piperacillin/Tazobactam
9%
Intrathecal Drug Administration
9%
Neutrophil Gelatinase Associated Lipocalin
9%
Calcineurin
9%
Pyonephrosis
9%
Pyelonephritis
9%
Urinary Tract
9%
Isograft
9%
Screening Cultures
9%
Emphysematous Pyelonephritis
9%
Robot-Assisted Prostatectomy
9%
Infection Control
9%
Fistula
9%
Omicron Coronavirus Variant
9%
Biopsy
9%
Febrile Neutropenia
9%
Kidney Tumour
9%
Partial Nephrectomy
9%
Da Vinci Surgical System
9%
Urologic Surgery
9%
Quinolone Derivative
9%
Prostate Secretion
7%
Postoperative Infection
6%
Antimicrobial Therapy
5%